- Rating
- 1
- Confidence
- 3
- Informativeness
- 2
- Presentation
- 3
- Soundness
- 2
Read review
Paper summary
This paper introuced a pocket-based molecule generation method targeting on modeling fragment-pocket interaction.
Critical strengths
- The benchmark is well-established with very comprehensive literature/baseline review as well as reasonable metrics. Multiple views were evaluated during the baseline comparison.
- The method was clearly presented.
Critical weaknesses
- Although the authors showed that using adaptive fragment-based generation can improve SA and diversity, the method is still not novel and insightful enough. There should be more insights and conclusions, for example, proposing a way to improve energy and affinity.
- The motivation for proposing such a method/these modules is not strong or supportive enough based on the experimental results.
- The overall performance is still not perfect. There should be more improvements to the method.
- More pocket-based generation methods should be compared in the benchmark table.
Questions for authors
See weakness.
5 comments
Motivation and Experimental Support
Thank you for raising this concern. The motivation for AFIMol is supported both by the problem each module addresses and by controlled experiments. It was also recognized in the other reviews: Reviewer 1 described the combination of adaptive fragmentation and residue-level interaction guidance as “well motivated”; Reviewer 2 considered adaptive fragmentation and pocket-conditioned fragment scoring “plausible ways” to represent molecules while retaining protein-context information.
SAF addresses a limitation of fixed fragmentation rules: they identify admissible cuts but do not rank alternative boundaries according to each molecule’s local context. Figure 2 shows that SAF produces fewer, larger fragments. The non-zero LM-only normalized gradient (0.012) further confirms that the generation objective supplies a learning signal to its boundary scorer. Consistently, removing SAF reduces SA from 0.788 to 0.765, Diversity from 0.771 to 0.753, and High Affinity from 0.589 to 0.523.
FIPRA addresses the need to distinguish candidate fragments by their compatibility with pocket residues. Removing it changes Vina from -7.241 to -7.082 and High Affinity from 0.589 to 0.520. Figure 3 provides complementary outcome-level evidence: median nearby-residue density changes by +0.060 and carbon-associated proximity by +0.047. These are geometric analyses, not contact-prediction accuracy measurements.
Finally, we examined synthetic feasibility beyond the SA proxy. For four representative molecules generated for pocket 4XLI, AiZynthFinder found top-ranked routes of 2–4 steps terminating in stock-listed precursors; the corresponding solved-route fractions were 28.0%, 32.3%, 37.9%, and 80.0%. These computational results support the relevance of the design objective, while experimental synthesis and activity remain to be validated. (Weakness2)
Overall Performance
Thank you for raising this concern about the overall performance of AFIMol. We agree that AFIMol does not lead on every metric, and do not claim otherwise. Its contribution is a competitive multi-objective performance profile.
AFIMol achieves Vina of -7.241, High Affinity of 0.589, QED of 0.596, SA of 0.788, LogP of 3.003, Lipinski-related score of 4.959, and Diversity of 0.771. In Table 1, AFIMol achieves the best reported SA and Diversity, while its High Affinity ranks second among methods reporting this metric (PMDM: 0.628). We acknowledge that several methods obtain more favorable mean docking scores.
Ablation experiments further demonstrate the complementary contributions of SAF and FIPRA:
Without SAF: SA decreases from 0.788 to 0.765, Diversity from 0.771 to 0.753, and High Affinity from 0.589 to 0.523.
Without FIPRA: Vina worsens from -7.241 to -7.082 and High Affinity decreases from 0.589 to 0.520, although QED and Diversity increase to 0.625 and 0.782, respectively.
Without both modules: The model obtains its least favorable Vina (-6.789), SA (0.671), and Diversity (0.711).
These non-monotonic changes demonstrate that the two modules contribute to different, partially competing objectives rather than uniformly improving every metric.
Evaluation scale and consistency. We evaluate 100 test pockets, performing 1,000 sampling attempts per pocket and retaining 100 valid, unique molecules. This yields 10,000 evaluated molecules. The full model and all ablations follow identical sampling, filtering, docking, and evaluation procedures.
Overall, these results demonstrate the complementary contributions of SAF and FIPRA and AFIMol's favorable balance across multiple molecular-generation objectives, rather than universal superiority on every individual metric. (Weakness3)
Methodological Novelty and Research Insights
Thank you for this comment. We agree that binding affinity is an important objective, but argue that pocket-conditioned molecular generation should not be judged by docking score alone. A useful candidate must also be synthesizable, drug-like, and structurally diverse.
Table 1 illustrates this trade-off. AMDiff obtains a more favorable Vina score than AFIMol (-7.466 vs. -7.241), but has lower QED (0.479 vs. 0.596), SA (0.681 vs. 0.788), and Diversity (0.729 vs. 0.771). PMDM also reports better Vina (-7.572) and High Affinity (0.628 vs. 0.589), but substantially lower SA (0.611) and Diversity (0.709). Thus, better docking scores do not necessarily translate into better overall molecular-generation quality.
AFIMol’s methodological insight is to model two complementary decisions within fragment-autoregressive generation: SAF learns molecule-dependent priorities among chemically admissible fragmentation boundaries, while FIPRA evaluates each candidate fragment through residue-level, candidate-conditioned pocket interaction reasoning and adjusts its generation logit. This is more specific than simply combining fragments with global pocket conditioning.
We agree that explicit energy- or affinity-guided optimization is a valuable direction. However, adding such an objective does not automatically improve overall candidate quality and may shift the balance among binding, synthesizability, and drug-likeness. AFIMol therefore focuses on improving this balance rather than claiming to minimize docking energy universally. (Weakness 1)